Is something significant happening right under our noses?
There is a change that has quietly crept up over the past few decades — so gradual that most people have barely noticed. Since the 1970s, doctors have slowly lowered blood pressure targets. That has provided justification to prescribe more and more blood pressure pills to an ever-increasing percentage of the population.
Is there some grand conspiracy at work to push Big Pharma drugs onto people? Or is there genuine evidence to adopt more aggressive blood pressure targets? The question matters especially now, given that new blood pressure guidelines published in 2025 have updated the wording on what levels people should actually aim for.
Blood pressure is one of the most widely measured health metrics in the world — and also one of the most commonly misunderstood. The debate over what constitutes a "normal" reading is not merely academic. It has real-world consequences for who gets treated, who gets medicated, and who might be left at elevated risk without knowing it. To evaluate whether the lowering of blood pressure targets reflects genuine science or industry influence, it is necessary to understand both the historical record and the current evidence base.
Table of Contents
The Narrative
It is worth taking a careful look at what is going on. Because if the medical community is pushing certain blood pressure targets just to line the pockets of drug companies, that is a serious problem.
Starting by asking why someone might think that is the right place to begin.
On the surface, there is some data that could look suspicious. Each time the threshold of what counts as "high blood pressure" moves lower, more people are diagnosed with a medical problem that needs attention. If someone was sitting at a blood pressure of, say, 140 in 1980, their doctor would have said, "No problem. You're healthy."
But now, that same person would be diagnosed with stage 2 hypertension — which sounds pretty serious. And, as it happens, pharmaceutical companies sell pills that can bring that blood pressure level down.
So as the thresholds have changed, hypertension — the medical term for high blood pressure — has gone from being relatively rare to affecting nearly half the adult population in the U.S. That number reaches almost 72% for those 60 and older [1].
That is potentially a huge number of prescriptions for anti-hypertensive medications. And it has translated into equally large sums of money. In 2025, the global market for these medicines is estimated to be over $22 billion — and the demand is rising [2].
So the concern circulating on social media is this: it is Big Pharma that is really driving the changes in blood pressure targets [3].
A Look at the History
The medical community's response to this concern is straightforward: blood pressure targets are driven by evidence from compelling studies, and they change because the science keeps getting better.
Who is right? To sort this out, it helps to look at how we got here.
Going back to the 1940s, the idea of what counted as high blood pressure was — by today's standards — quite high. In a cardiology textbook published in 1948, the author defined high blood pressure as above 180/110 [4].
But there was another key aspect of how blood pressure was understood at the time. Elevated blood pressure was not seen as a problem in itself — it was only a concern if it was already causing visible damage, such as enlargement of the heart muscle [4].
This was a strange attitude to hold, even back then. Because evidence had already emerged, several decades earlier, that elevated blood pressure was linked to a greater risk of early death.
The year was 1925. One of the most consequential medical discoveries ever made was just published — and it did not come from doctors or scientists. It came from mathematicians.
They were the actuaries who crunched numbers for life insurance companies to figure out who was at the greatest risk of dying young. And their data was telling an unmistakable story. There was one basic health indicator strongly linked to heart attacks, strokes, and early death. That indicator was blood pressure [5].
Blood pressure measurements had only become part of insurance applications in the decade before. But by 1925, the data from over 700,000 individuals made the trend abundantly clear. The link between elevated blood pressure and premature death was not just statistical noise — it was a dose-response relationship. The higher the blood pressure, the greater the risk [5].
This conclusion rested on a massive dataset. But it was largely ignored by the medical community — which is why that 1948 textbook was not particularly worried about elevated blood pressure in most patients.
That began to change in 1957 when the early results from a groundbreaking study were published.
That study was the Framingham Heart Study. Launched in 1948 to investigate the causes of heart disease, it recruited over 5,000 adults aged 30 to 62 from the town of Framingham, Massachusetts [6]. Researchers planned to follow this group over the long term and identify which factors were linked to those who developed heart disease.
Just four years into the study, something unmistakable emerged from the data. There was a significant association between high blood pressure and the development of heart disease [7].
This finding carried profound significance. It raised the possibility that elevated blood pressure — on its own — was a genuine health risk, not merely a symptom of something else.
But confirming this required clinical trial data.
One of the most important early trials was conducted by the U.S. Veterans Administration and published in 1967. It enrolled 143 men with severe hypertension — split between a group taking blood pressure medications and a placebo group. Over the study period, the placebo group experienced 27 severe blood-pressure-related health events. The treatment group had just 2. The researchers concluded that controlling blood pressure provided a significant benefit [8].
As evidence from studies like the Framingham Heart Study and trials like this accumulated through the 1970s, the first authoritative guidelines for blood pressure were published.
They came from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure — known as the JNC. Their 1977 report recommended that doctors keep a close eye on anything over 160/95. Levels over 140/90 should also be monitored to check whether they were rising. No treatment was recommended until the diastolic number — the lower figure in a blood pressure reading — reached 105. That is a relatively high threshold by today's standards: it would now be classified as stage 2 hypertension. Importantly, the 1977 report made no recommendations based on the systolic number [4].
So the progression was already underway. The 1948 textbook used a threshold of 180 as a level of concern. The 1977 JNC report moved that down to 160. Each shift was driven by a mixture of observational studies and clinical trials establishing a clear link between elevated blood pressure and heart-related problems.
The 1984 JNC report went further: it was the first to define hypertension based on systolic blood pressure — the upper number in a reading — placing the threshold at 140 [9].
What justified setting it at that level? At that time, most existing evidence centred on diastolic blood pressure. The 1984 report cited a number of clinical trials showing benefits from treating what was then considered mild hypertension — meaning a diastolic blood pressure of at least 90 [9].
The reasoning was that a systolic threshold of 140 roughly corresponded to the same risk profile as a diastolic level of 90. Those pairings are still reflected in standard blood pressure charts today [10].
The overall case for setting the threshold at 140 rested on a consistent finding: the lower the blood pressure, even within what was considered the normal range, the better the health outcomes [9].
That level of 140 remained the clinical standard for decades. But beginning in the early 2000s, a series of new findings began to challenge even that benchmark.
The first appeared in the prestigious journal The Lancet in 2003. It was a massive analysis of data from one million adults across 61 separate studies. Researchers examined the relationship between blood pressure and death — particularly from heart attacks and strokes [11].
At that point, there was already plenty of evidence showing a continuous link between elevated blood pressure and cardiovascular risk. As blood pressure came down, risk fell too. But what had not been established was exactly how low blood pressure could go and still show continued improvement in outcomes. The standard target at the time was below 140.
What this large analysis revealed was striking: the benefits of lower blood pressure did not level off at 140. The relationship between lower pressure and better outcomes continued all the way down to at least 115 [11].
The implications were substantial. At 140, significant potential health gains were still being left on the table.
It was on the strength of evidence like this that official guidelines made a major revision in 2017. Normal blood pressure was redefined as below 120. Readings between 120 and 129 were classified as elevated. Stage 1 hypertension was set at 130 to 139, and stage 2 at 140 and above [12].
The implication was clear: ideally, the goal is to stay below 120. The guideline authors noted that the evidence was substantial — cardiovascular risk rises even as blood pressure climbs above that level [12].
There was solid evidence supporting these recommendations at the time. Since 2017, three additional studies have strengthened those conclusions further.
The first, called the SPRINT trial, was published in 2021. The participants were at high cardiovascular risk but did not have diabetes or a prior history of stroke. They were divided into two groups: one aiming for a blood pressure below 140, and the other aiming for below 120.
The results were so definitive that the trial had to be stopped early. It was designed to run for 4 to 6 years — but after just 3.3 years, the data made the answer clear. There was a 27% lower annual risk of heart attack, stroke, or death from cardiovascular causes in the group targeting below 120 [13].
When it came to overall mortality, the lower-target group had a 25% lower risk of dying during the study period [13].
A 25% reduction in the risk of death from more aggressive blood pressure control is a clinically significant finding — not a marginal benefit. It is worth pausing to appreciate what this means in practical terms: the difference between targeting below 140 and below 120 was enough to change survival outcomes at a population level within just over three years. For a lifestyle and medication intervention, that is a remarkable effect size.
The story did not end there. A subsequent study in China tested these findings on an even larger, more diverse population: over 11,000 people, including those with diabetes and those who had previously experienced a stroke.
The results were consistent. Lowering systolic blood pressure to below 120 reduced the risk of heart attacks, strokes, and cardiovascular death by 12% [14].
It also cut the overall risk of death from any cause by 21% over three and a half years [14].
The data continued to accumulate. A new analysis of SPRINT data focusing on dementia risk was published in 2025. The same pattern held: those assigned to the lower blood pressure target had a 14% lower probability of developing dementia during the follow-up period [15].
The historical record tells a consistent story. Blood pressure thresholds have not been lowered arbitrarily. Each revision has followed accumulating evidence that levels previously thought to be safe were, in fact, associated with elevated risk. The current evidence supports a target systolic blood pressure below 120 for most adults — with the important caveat that for some older adults, a slightly higher level may represent a more appropriate balance between competing risks and benefits. Individual clinical decisions should be made in consultation with a healthcare provider who can weigh personal risk factors, medications, and overall health context.
The evidence rests on a substantial body of both observational and clinical trial data, spanning decades of research and millions of participants.
The primary source of confusion on this topic is not the pharmaceutical industry. It is the misinformation spread by health commentators online, who encourage people at genuine cardiovascular risk to disregard evidence-based guidance — often in favour of narratives that are more compelling than they are accurate.
New Guidelines Released
New blood pressure guidelines were published in 2025. How do they change the picture? Have the thresholds been lowered yet again?
No. The numerical thresholds for elevated blood pressure and hypertension have not changed. What has changed is the recommended approach — and the urgency behind it.
The 2025 guidelines recommend that those with hypertension and elevated cardiovascular risk aim for at least below 130 mmHg systolic, with a preference for 120 or below [16].
The guidelines also recommend beginning treatment for elevated blood pressure earlier. In lower-risk categories, this starts with lifestyle changes. If targets are not met within 3 to 6 months, medication becomes appropriate [16].
Part of the rationale for this more aggressive approach is the growing and striking body of evidence on the link between blood pressure and dementia risk [16].
On dietary changes, the 2025 guidelines now recommend lowering salt intake — even for people whose blood pressure is currently within a normal range [16].
They also highlight the potential role of salt substitutes. These products typically combine standard sodium chloride with potassium chloride. This combination lowers sodium intake while simultaneously increasing potassium intake. Both changes are independently associated with reductions in blood pressure. The guidelines specifically emphasise salt substitutes as a practical dietary tool — one with a meaningful evidence base and few downsides for most healthy adults [16].
The guidelines additionally set a weight-loss target of 5% of body weight as an effective strategy for lowering blood pressure in people who are overweight or obese [16]. Even modest reductions in body weight can translate to meaningful improvements in blood pressure readings, particularly when combined with the dietary changes the guidelines recommend.
Taken together, the 2025 guidelines reinforce a key message: blood pressure management is not only about whether to take medication. Diet, salt intake, potassium intake, and weight all have roles to play — and the evidence supports starting those interventions earlier than many people currently do.
References
- https://www.cdc.gov/nchs/products/databriefs/db511.htm
- https://www.statista.com/outlook/hmo/pharmaceuticals/anti-hypertensive-drugs/worldwide
- https://rxbalance.org/whos-setting-your-health-goals-your-doctor-or-big-pharma/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8109518/
- https://www.google.com/books/edition/Blood_Pressure/PjvQAAAAMAAJ?hl=en&gbpv=1
- https://www.framinghamheartstudy.org/fhs-about/history/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC1550985
- https://jamanetwork.com/journals/jama/article-abstract/336799
- https://ostemed-dr.contentdm.oclc.org/digital/api/collection/myfirst/id/3922/download
- https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings
- https://pubmed.ncbi.nlm.nih.gov/12493255/
- https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065
- https://www.nejm.org/doi/10.1056/NEJMoa1901281
- https://pubmed.ncbi.nlm.nih.gov/38945140/
- https://www.neurology.org/doi/abs/10.1212/WNL.0000000000213334
- https://jamanetwork.com/journals/jama/fullarticle/2841006
